Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services. Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns. Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise. By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Xellsmart develops stem cell treatment solutions for a variety of degenerative diseases for which there are now no clinical treatments. Xellsmart is located in Minhang District, Shanghai, China.
Chime Biologics, is a world-class experienced Contract Development and Manufacturing Organization (CDMO), providing customer-centric and cost-effective services for timely premier-quality biopharmaceutical development and manufacturing. We provide a comprehensive solution supporting our customers from analytical and process transfer to early-stage biopharmaceutical development through late-stage clinical and commercial drug substance and drug product manufacturing for Global Supply.
Eco Polymer specializes in designing and manufacturing plastic tubes and parts. They provide products for polyethylene, polypropylene, polyamine, elastomers, fluoropolymers, and other various polymers. They serve the medical instrument, auto, electronics, fiber optics, semiconductor, chemical engineering, environment, and analytics industries.
Ehomepoct is a healthcare management company that offers rapid diagnosis and health management services. They develop application and products of artificial intelligence in the area of medical treatment.
Degron Therapeutics is a drug discovery platform. They provide the discovery and development of a new class of targeted protein degradation therapeutics and small molecule molecular glue degrader drugs. Degron Therapies aspires to be a global leader in the discovery and development of small molecule molecular glue degrader (MGD) medicines, a new class of targeted protein degradation therapeutics. Degron has assembled a team of world-class executives and scientific leaders to apply its scientific expertise to the identification and validation of disease targets, particularly those that are inaccessible to conventional small molecule inhibitors, as well as novel selective MGD compounds to address unmet medical needs across all therapeutic areas.
Resproly specializes in the research, development, production, and sales of formulas and equipment for respiratory inhalation. The company is dedicated to creating inhaled formulations and pulmonary drug delivery technologies aimed at addressing various respiratory diseases, including Asthma and Chronic Obstructive Pulmonary Disease (COPD). Additionally, Resproly is involved in developing treatments for other clinically significant conditions such as diabetes and Parkinson's Disease, positioning itself as an integrated enterprise focused on multiple demanding treatment areas.
Nuoer Medical was established in August 2017, focusing on the field of functional neurosurgery, with precise EEG as the entry point, providing integrated diagnosis and treatment solutions for various diseases caused by abnormal discharge of the nervous system.
Biocreatech is a biotechnology firm that uses protein design and synthetic biology to create cell factories capable of producing a range of products such as drug intermediates, fine chemicals, functional peptides, and therapeutic proteins. They involve in integrating multiple proteins into molecular machines in order to transform cells into factories.
Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.
Tripod is a Contract Research Organization in the biopharmaceutical space that provides preclinical research services for global pharma companies, R&D enterprises and institutes, and medical device developers. Tripod (TPR) is dedicated to nonclinical research (drug safety evaluation) for the candidates of new chemical entity (NCE), food additives, biologics，pesticides，veterinary drugs, and new cosmetics.
Shanghai Bailige Biotechnology Co., Ltd. integrates professional management, R&D, production, and service teams.Bioligo establishes and provides high-quality DNA synthesis/sequencing, experiments, production, and various customized services.
Kang Liming Bio is a biomedical technology company that specializes in the development, production and sales of tumor screening diagnostic products such as colorectal cancer fecal non-invasive screening kits.
Boan Biotech is a biopharmaceutical company developing therapeutic antibodies with a focus on key therapeutic areas including oncology, metabolism, autoimmunity, and ophthalmology.
Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.
NeuExcell is an early stage gene therapy company focusing on neurodegenerative diseases. We have developed a disruptive neural repair technology that utilizes in vivo astrocyte-to-neuron conversion. Our vision is to improve the quality of life of millions of patients worldwide who are suffering from neurodegenerative conditions by using the power of gene therapy to restore damaged neural tissue.
Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.
Next Generation Gene Therapeutics
Series A in 2021
Next Generation Gene Therapeutics is a healthcare company that engages in the research and development of gene therapy. Its unique propriety technology of "one target and two bullets" can provide effective treatment for a variety of genetic diseases that currently have few therapeutic methods in the world. NGGT was founded in March 2020 by senior scientists and entrepreneurs in the field of gene therapy. It is committed to becoming the world's leading gene therapy company with international influence. The company has successful experience in the whole industry chain, concerning the early development of gene therapy products, the large-scale production of viral vectors, the construction of quality standards, international multi-center clinical research, and the application for the marketing of gene therapy products.
Brattea is a medical device research and development company. Brattea focuses on the development and commercialization of renal denervation products with indications in hypertension, cancer pain and diabetes.
Synaptic Medical is a medical device company focused on developing and commercializing breakthrough products for the treatment of cardiac arrhythmias and other cardiovascular diseases. Their mission is to develop unique, cost-effective, and clinically advanced technologies with the highest quality to enable physicians to optimize and expand treatment options. The company was founded in 2005 in Minnesota.
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our company management and advisors consist of veteran pharmaceutical executives with multiple prior successes in the development of many blockbuster biologics currently in the market. Tavotek has 3 diverse R&D platform for biologics: TavoSelect (an innovative Phage Display Library), TavoPrecise (engineering platform for tissue-specific biologics), and TavoMIP (a multicyclic peptide platform). Along with these platforms, Tavotek has a rich and diverse pipeline of product candidates in various stages of development, focused on cancers, autoimmune conditions, and infectious diseases.
Huikai Medical is a company that specializes in the production and R&D of medical devices for the urinary system. Its products include prostatic hyperplasia, stone treatment, urinary incontinence, urological tumors, and novel materials.
VesiCURE Therapeutics engages in the research and development of exosome innovative drugs. The company focuses on the research and development of exosomal (extracellular vesicles, EV) drugs, promoting the establishment and improvement of the exosomal pharmaceutical industry chain. The company was founded in 2021and is based in Suzhou, Jiangsu, China.
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product line includes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level.
GensKey is a genetic testing medical diagnostic service provider that applies high-throughput sequencing technology to pathogen diagnosis to solve a series of difficulties in the detection rate, timeliness and accuracy of pathogenic diagnosis, so that many patients with severe infections get timely and accurate. Diagnosis.
Zylox Medical Device Co. was founded in the beautiful city of Hangzhou in 2012 by a group of highly skillful and experienced returnees from the US and Europe. They have on average 5-20 years of working experiences in various functional areas such as research and development, management, and manufacturing in leading device makers including Johnson & Johnson, Medtronic, and Abbott before returning to China. Since its inception, Zylox has developed an increasingly rich product pipeline of interventional and implantable peripheral vascular devices such as PTA balloons, PTA drug-coated Balloons (PTA DCB), superficial femoral artery (SFA) stent, drug-eluting SFA stent, and other vascular accessories. Zylox strives to continuously innovate and provide patients with superior quality medical devices.
Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.
X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.
Shanghai Baixin'an Biotechnology Co., Ltd. is to develop independent innovative products in the future, continuously develop high-value minimally invasive therapeutic products, provide better medical products and technologies for medical workers and patients, and make the largest medical and health care business. s hard work.
Rice and millet is China's leading platform services for children with autism spectrum, from 2014 Nian 9 Yue Jiang Ying Shuang (rice) founded the "rice and millet" micro-channel public number. It now provides integrated services such as rehabilitation services, integrated education support, parent training, online courses, and popular science information.
EOC Pharma is an integrated biopharmaceutical company that is focused on the manufacturing, development and commercialization of innovative global oncology products in China. They have adopted a licensing model in order to build EOC’s innovative pipeline by plugging their partner’s molecule into EOC’s “core engine” of local manufacturing, clinical development, regulatory filing, and commercialization. The company has a pipeline of seven novel products from global biopharmaceutical partners that are potentially first- and best-in-class. Until now, EOC has obtained four Class I innovative drug CTA approvals and initiated clinical studies of four lead products in China.,EOC has a team of entrepreneurs and consultants with overseas background that boasts of first-class pharmaceutical R&D expertise as well as rich industry experience. The company owns an 8,000 square meter cGMP manufacturing facility in Taizhou, China Medical City and has offices in Shanghai, Beijing, Hong Kong and Los Angeles. EOC will leverage forward-looking licensing which will provide product opportunities to their integrated platform, generating a highly strategic portfolio. Ultimately, this will position EOC at the top of oncology innovation in China.
Ruixun Biotech is a healthcare company that provides biotechnology. Ruixun Biotech combines microfluidics, optics, precision instruments, electronic engineering, and biochemical technologies to create upstream equipment and consumables for molecular diagnosis and genetic testing. They released a number of products, including the digital PCR apparatus DropX-2000 and more than 50 different RUO detection kits.
DiaMonTech is developing a medical device for non-invasive measurement of blood sugar values. The patented process uses laser technology to determine and control blood glucose values of diabetes patients without any pain and without drawing blood.
Antai Kangcheng is a research and development company for tumor electric field treatment technology, focusing on the development of innovative tumor treatment methods, equipment and equipment for central nervous system injury repair and rehabilitation. Antai Kangcheng has also established a precise and optimized treatment planning system based on biophysical models and multimodal imaging systems, and is committed to developing a personalized tumor electric field treatment system suitable for Chinese patients.
Just Medical is an artificial orthopedic implant device and system developer. Just Medical provides hip knee and average staircase therapy for all surgical product solutions. Just Medical is committed to providing medical products and services that are safe and effective. It maintains high-speed development, and excellence, and gradually improves the product system in order to help doctors and end the patient's pain.
Joinspine
Series A in 2019
Joinspine is one of the few Chinese companies that have some core patients in the field of spinal surgery and spine endoscopy industry. The current team is using the latest new technologies to improve its auxiliary robot and AI. Based on advanced foreign technologies and their own Development, Jlecheng Medical believes they can help this industry to improve in China.
Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product line includes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level.
Allist Pharmaceuticals is a pharmaceutical enterprise that discovers, develops, and commercializes innovative medicines. Allist Pharmaceuticals is oriented by unmet clinical demands in the global pharmaceutical market, with a special focus on tumor treatment, under the development concept of advancing long life through scientific and technological innovation. Allist Pharmaceuticals develops medicines with the commitment to creating safe, effective, and inclusive innovative drugs with independent intellectual property rights.
Yidianling is a psychological counselling platform that provides free mental health services such as free questions and answers, psychological tests, expert services, and training lectures.
Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.
CART Medical Technologies, Ltd. is a high-tech company specializing in the development and application of new technologies for immune cell therapy. It has a 2,200 square meter GMP laboratory and research and development laboratory.
DeepCyto is a medtech company that focuses on digital hematology pathology and diagnostic equipment development. It introduces artificial intelligence and deep learning technology into the field of intelligent medical diagnosis and medical data analysis. The company was founded in 2018 and is based in Suzhou, Jiangsu, China.
AGS MedTech designs and develops products and surgical solutions in the field of interventional diagnosis and treatment. They provide patients and clinicians with endoscopic, minimally invasive diagnosis and treatment devices, helping patients reduce pain, and medical costs.
Established in 2006 in Beijing, Innovita Biological Technology Co., Ltd. is a Chinese high-tech enterprise specialized in R&D, manufacturing, marketing and after-sales service of In-vitro diagnostic tests. In 2011 Innovita extended a new plant in Tangshan city of Hebei province-Innovita (Tangshan) Biological Technology Co., Ltd., which was designed as five new production lines: colloidal gold, real-time PCR, chemiluminescence, ELISA and biochips. The facility covers 250 acres (160,000 square meters) and is equipped with a purification plant of 4,000 square meters. The designed annual output can reach 20 million tests. Currently they have got ten invention patents. With certification of CE, ISO 13485 and GMP, Innovita has an extensive product line covering Fertility, Infectious Diseases, Sexually Transmitted Diseases, TORCH, Respiratory Diseases, Drug Abuse, Tumor Marker and Cardiac marker tests.
Kanova is a biopharmaceutical company that focuses on developing therapeutic antibodies and innovative combination therapies in immuno-oncology and autoimmune diseases.
Neighboring good doctors
Series A in 2018
Neighboring good doctors is providing users with speedy calls, teletext consultation, face consultation, referral, etc.
Neighbor Doc is an online platform that provides healthcare services. The organization is dedicated to developing a new model of innovative medical services and establishing itself as a reputable medical service provider. Their objective is to thoroughly improve the capabilities of community medical services, and they combine general practice and specialty care, online and offline, and medical and health models.
Demei Medical specializes in the design and manufacture of sports medicine surgical equipment, intraoperative consumables, and rehabilitation products, with a focus on arthroscopic surgery and sports rehabilitation products.
Ningbo Senscure Biotechnology Co., Ltd, is specialized in innovation and improvement of minimally invasive surgery technology, with single incision laparoscopic surgery (SILS) and natural orifice transluminalendoscopic surgery (NOTES) as main focus, put emphasis on tumor treatment, and provides complete medical equipment solution for minimally invasive surgery.
Cryofocus Biotech is a Shanghai-based cryoablation device manufacturer, focusing on the application of cryogenic technology in the field of cardiovascular interventional therapy.
Founded in 2004, Smartee is a leading provider of digital invisible orthodontic solutions in China. As of March 2022, Smartee’s 23.6 million sets of clear aligners have successfully served orthodontic consumers worldwide. Smartee is headquartered in Shanghai, China, and overseas headquarters were established in the UK in 2021. Smartee’s production and R&D base are in Jiaxing Science and Technology City. Smartee currently has over 1,700 employees including a medical team of over 380 members led by professional PhD Orthodontists working in the Smartee Invisible Orthodontic Clinical Medical Center. Our large scale automated intelligent production base in China's "Dental Valley" (Ziyang, Sichuan) serves domestic China and the global market. As one of the leading brands in China’s invisible orthodontics industry, Smartee has introduced 3D printing technology into the field of stomatology instruments production in China and for the first time realized the large-scale production of customized clear aligners. "Innovation" is in the DNA of Smartee. Smartee bracketless invisible orthodontic technology combines clinical stomatology, computer science, biomechanics, 3D printing, and polymer material science, and has achieved a total of over 500 patents since March 2022. Smartee has a database of over 520,000 orthodontic cases, which is growing at a rate of more than 100% per year. It is recognized as one of the most innovative and growing high-tech companies in the field of stomatology R&D and production in China. Smartee's efforts and contributions in promoting the development of the Chinese invisible orthodontic industry have been fully recognized and accepted by all sectors of the industry. It is a member of the 3D Printing Medical Devices Committee of the China Association for Medical Devices Industry, a member of the team that jointly drafted the Chinese oral digitalization wording standard，a standing committee member of the Chinese Stomatological Association, an executive director unit of the Shanghai Medical Instrument Trade Association, and has obtained various honorary titles such as National Hightech Enterprise and Shanghai Little Giant Enterprise. In 2015, KaVo Group, the world's leading manufacturer of dental equipment and consumables, became a shareholder of Smartee, which announced that KaVo Group had made a strategic layout for the promising field of invisible orthodontics. In 2018, Smartee began working with the world-famous University of North Carolina (UNC) School of Dentistry to jointly research and develop orthodontic clinical medicines and clear aligners related to biomechanics and medical polymer materials. In 2019, Smartee officially became a strategic cooperative partner of China Aerospace. The two would fully combine their respective technological and resource advantages and launch a series of strategic cooperations. Smartee joined hands with China Aerospace to advance the development of China's orthodontic industry. Meanwhile, Smartee worked together with the orthodontic team led by Professor Shen Gang to develop Smartee S8 S9 S10 mandibular repositioning invisible orthodontic solutions. Smartee also completed series C funding in the same year. Investors include well known domestic and foreign industry funds and investment agencies in the medical field with solid financial strength. In 2020, Smartee cooperated with the orthodontic team led by Professor Shen Gang for the second time to develop S11 alveolar orthopaedic technology, and for the third time to start the research and development of S12 invisible and fixed fusion orthodontic technology, S16 Invisible forward traction technology. In the same year, Smartee launched a series of innovative products and technology such as multi-layer sheets and S15 Smartee Hook traction technology. In 2021, Smartee continued its cooperation with Professor Shen Gang to develop S17, S18, S19, the mandibular maintenance and perioperative orthodontic solutions. In 2022, Smartee was officially authorized to use Disney and Marvel IPs for its new Smartee Teen products for children and teenagers. With the launching of Smartee Teen, Smartee has been able to provide consumers of all ages with orthodontic correction management. In March 2022, Smartee closed its series D funding round of US$ 80 million. This round of financing will continue to accelerate its expansion in the global orthodontic industry. In the future, guided by brand and driven by innovation and capital, Smartee will adhere to the medical essence of invisible orthodontics and provide safe, efficient, and comfortable invisible orthodontic products and services to global consumers and doctors, and make healthy and beautiful smiles predictable.
LenoMed Medical is a medical equipment maker. Over 15-year research and development experience on infusion technology, LenoMed innovatively develop and manufacture InnoTech insulin pump, drug infusion pump and disposables. They explore innovative way to develop close-loop through integration of CGM technology and insulin pump. They share the commitment to advance diabetes management through their diabetes care management system.
AI Therapeutics was founded in 2013 with a mission to advance the clinical development of new therapies to treat Lymphangioleiomyomatosis (LAM) and other diseases. Working with a dedicated team of scientific, clinical, and drug development experts, AI Therapeutics expects to use its disease-specific focus and technological approach to identify and advance drugs that will provide significant therapeutic benefits for LAM patients. AI Therapeutics develops drugs for rare diseases and cancer. LAM takes advantage of the inflection point in biological understanding and computer science, leveraging big data from NextGen sequencing, genome editing, chemical genomics, and combinational drug screening, to develop precision therapeutics and companion diagnostics. LAM has advanced two drugs into the clinic: LAM-001 for lymphangioleiomyomatosis, and LAM-002 for B-cell non-Hodgkin lymphoma.
Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.
IMPACT Therapeutics creates new treatments to treat cancer and other life-threatening disorders. The firm is committed to the discovery and development of targeted anti-cancer treatments based on synthetic lethality, hence offering patients novel targeted anti-cancer drugs.
Ascentage Pharma develops novel small-molecule therapies for cancer, hepatitis B, and age-related diseases. They have developed a pipeline of seven drug candidates that disrupt complex and difficult-to-target protein-protein interactions and are next-generation tyrosine kinase inhibitors.
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.
inui Health is a consumer medical diagnostics company based in Silicon Valley. Their vision is to make medical-grade information accessible anytime, anywhere. Their cloud-based diagnostic platform works in a mobile environment to empower consumers with access to their own health information. Their products will help consumers detect complications early, monitor their health, and easily share their health information so they can work with their healthcare provider for timely interventions. The first product to be released will be the inui In-Home Urine Analysis test system, which provides patients and physicians with immediate lab test results.
Admera Health is an advanced molecular diagnostics company focused on personalized medicine and non-invasive cancer testing. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health will fulfill unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation sequencing technologies and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, payers, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.
Nano-Micro Technology manufactures monodisperse particles in a range of sizes and serves a variety of industries and applications. They provide solutions such as configurable resin development and purification process development. The company's contact modes are phone and physical address.
MID Labs was founded by Dr. Carl Wang in 1981 and has been associated with vitreoretinal surgery from its infancy. Not only has MID Labs invented the tools for modern vitrectomy, but as a company, it has been instrumental in revolutionizing the ophthalmic field through its products. MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Established in 2001, Eddingpharm’s vision and mission has always been to become China's leading supplier of patented drugs and branded drugs, bridge the gap between Chinese patients and global high quality medicines. They constantly acquired classic branded medicines from MNCs, that benefits Chinese patients through our effective operation cost management and expansion to the low-tier medical terminals. On the other hand, they keep exploring and innovating. Eddingpharm continuously introduce abroad patented drugs to China market, participate in international multi-center clinical trials and strive to realize simultaneous launch of new drugs in China and globally, providing physicians with more treatment options. Over the past few years, they rapidly expanded our business and strategically deployed resources in various fields. They are upgrading to a whole-industry-chain entity from sole in-licensing R&D and commercialization. Eddingpharm has nearly 1,000 professional representatives in 30 provinces across the country, with coverage of 19,000+ hospitals and 20,000+ pharmacies. Over the years, they have collaborated with multinational pharmaceutical companies, specialty pharmaceutical companies and leading R&D institutions to enrich our product portfolio by in-licensing patented drugs, setting up JV, gaining exclusive distribution rights and forming strategic alliances. Our focused therapy areas have been expanded to anti-biology, oncology, respiratory, cardiovascular and renal diseases. In addition, our several new drugs under development or regulatory registration are expected to be launched in the near future. The revolutionary product Vascepa® capsule is a single-molecule prescription product consisting of the icosapentaenoic acid commonly known as EPA in ethyl-ester form. Its ability has been verified that lowering triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. The ability of reducing residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, has been published in The New England Journal of Medicine in November 2018. Additional results and analysis of total recurrent events observed were subsequently published in the Journal of American College of Cardiology in March 2019. Recently, supplemental new drug application (sNDA) for Vascepa® capsules reducing cardiovascular risks has been accepted for filing and granted Priority Review designation by the US FDA. Eddingpharm has been granted the rights of development, commercialization and supply of VASCEPA® in mainland China, Hong Kong, Macau and Taiwan since 2015, also including the management and sponsor of pivotal clinical trials for registration. They have completed a pharmacokinetic (PK) study in China and a racial comparison study of PK characteristics between Chinese and American healthy subjects. Phase III clinical trial is currently in progress. "Professionalism, excellence, responsibility, and persistence" are the values of Eddingpharm. Our profession is related to life and health, professionalism is the fundamental principle. Excellence runs through every minute of our work. Responsibility is our attitude towards each task. In the face of our beliefs and missions, they will stick to persistence and never give up. They are moving towards the goal that Chinese patients benefit from the world's best medicines and cutting edge medical technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.